World Health Organisation (WHO). International Classification of Diseases 11th Revision (ICD-11). 2022. icd.who.int/en. Accessed 26 June 2024.

Pauling JD, Hughes M, Pope JE. Raynaud’s phenomenon - an update on diagnosis, classification and management. Clin Rheumatol. 2019;38(12):3317–30. https://doi.org/10.1007/s10067-019-04745-5.

Article  PubMed  Google Scholar 

Gerbracht DD, Steen VD, Ziegler GL, Medsger TA Jr, Rodnan GP. Evolution of primary Raynaud’s phenomenon (Raynaud’s disease) to connective tissue disease. Arthritis Rheum. 1985;28(1):87–92. https://doi.org/10.1002/art.1780280114.

Article  CAS  PubMed  Google Scholar 

Block JA, Sequeira W. Raynaud’s phenomenon. The Lancet. 2001;357(9273):2042–8. https://doi.org/10.1016/S0140-6736(00)05118-7.

Article  CAS  Google Scholar 

Garner R, Kumari R, Lanyon P, Doherty M, Zhang W. Prevalence, risk factors and associations of primary Raynaud’s phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 2015;5(3): e006389. https://doi.org/10.1136/bmjopen-2014-006389.

Article  PubMed  PubMed Central  Google Scholar 

Haque A, Hughes M. Raynaud’s phenomenon. Clin Med. 2020;20(6):580–7.

Article  Google Scholar 

Fardoun MM, Nassif J, Issa K, Baydoun E, Eid AH. Raynaud’s phenomenon: a brief review of the underlying mechanisms. Front Pharmacol. 2016. https://doi.org/10.3389/fphar.2016.00438.

Article  PubMed  PubMed Central  Google Scholar 

Fraenkel L, Zhang Y, Chaisson CE, Maricq HR, Evans SR, Brand F, et al. Different factors influencing the expression of Raynaud’s phenomenon in men and women. Arthritis Rheum. 1999;42(2):306–10. https://doi.org/10.1002/1529-0131(199902)42:2%3c306::AID-ANR13%3e3.0.CO;2-G.

Article  CAS  PubMed  Google Scholar 

Stjernbrandt A, Björ B, Andersson M, Burström L, Liljelind I, Nilsson T, et al. Neurovascular hand symptoms in relation to cold exposure in northern Sweden: a population-based study. Int Arch Occup Environ Health. 2017;90(7):587–95. https://doi.org/10.1007/s00420-017-1221-3.

Article  PubMed  PubMed Central  Google Scholar 

Nilsson T, Wahlström J, Burström L. Hand-arm vibration and the risk of vascular and neurological diseases—a systematic review and meta-analysis. PLoS ONE. 2017;12(7): e0180795. https://doi.org/10.1371/journal.pone.0180795.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laplanche A, Clavel F, Contassot JC, Lanouziere C. Exposure to vinyl chloride monomer: report on a cohort study. Br J Ind Med. 1987;44(10):711–5. https://doi.org/10.1136/oem.44.10.711.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khouri C, Blaise S, Carpentier P, Villier C, Cracowski J-L, Roustit M. Drug-induced Raynaud’s phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol. 2016;82(1):6–16. https://doi.org/10.1111/bcp.12912.

Article  CAS  PubMed  PubMed Central  Google Scholar 

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed, text rev.). 2022.

Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry. 1998;59(Suppl 7):4–16.

PubMed  Google Scholar 

Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiat. 2005;57(11):1442–51. https://doi.org/10.1016/j.biopsych.2005.04.001.

Article  PubMed  Google Scholar 

Wender PH, Tomb DA. Attention-deficit hyperactivity disorder in adults: an overview. Attention-Deficit Hyperactivity Disorder (ADHD) in Adults. 2010;176:1-37.

Agnew-Blais JC, Polanczyk GV, Danese A, Wertz J, Moffitt TE, Arseneault L. Evaluation of the persistence, remission, and emergence of attention-deficit/hyperactivity disorder in young adulthood. JAMA Psychiat. 2016;73(7):713–20. https://doi.org/10.1001/jamapsychiatry.2016.0465.

Article  Google Scholar 

Cortese S, Song M, Farhat LC, Yon DK, Lee SW, Kim MS, et al. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease study. Mol Psychiatry. 2023;28(11):4823–30. https://doi.org/10.1038/s41380-023-02228-3.

Article  PubMed  Google Scholar 

Polanczyk G, Silva de Lima M, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–8. https://doi.org/10.1176/ajp.2007.164.6.942.

Article  PubMed  Google Scholar 

Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015;135(4):e994–1001. https://doi.org/10.1542/peds.2014-3482.

Article  PubMed  Google Scholar 

National Institute for Health and Care Excellence (NICE). NICE guideline NG87 - Attention deficit hyperactivity disorder: diagnosis and management. 2018. https://www.nice.org.uk/guidance/ng87. Accessed 4 July 2024.

Briars L, Todd T. A review of pharmacological management of attention-deficit/hyperactivity disorder. The Journal of Pediatric Pharmacology and Therapeutics. 2016;21(3):192–206. https://doi.org/10.5863/1551-6776-21.3.192.

Article  PubMed  PubMed Central  Google Scholar 

Umair HM, Sandler RD, Alunno A, Matucci-Cerinic M, Hughes M. Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud’s phenomenon: a scoping review. Semin Arthritis Rheum. 2021;51(6):1200–4. https://doi.org/10.1016/j.semarthrit.2021.09.002.

Article  CAS  PubMed  Google Scholar 

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. https://doi.org/10.1038/clpt.1981.154.

Article  CAS  PubMed  Google Scholar 

Al Aboud A, Abrams M, Mancini AJ. Blue toes after stimulant therapy for pediatric attention deficit hyperactivity disorder. J Am Acad Dermatol. 2011;64(6):1218–9. https://doi.org/10.1016/j.jaad.2009.11.010.

Article  PubMed  Google Scholar 

Bayram Ö, Hergüner S. OROS-methylphenidate-induced Raynaud’s phenomenon: a dose-related side effect. J Child Adolesc Psychopharmacol. 2015;25(6):521.

Article  PubMed  Google Scholar 

Eynalli E, Metin O, Ray PC, Tahiroglu AY, Celik GG. Methylphenidate-induced Raynaud’s phenomenon. Psychiatry Clin Psychopharmacol. 2018;28:174–5.

Google Scholar 

Gaddam M, Zacharias R, He W, Oster J, Ostrow P, Schumaker G, et al. Dozing off is a problem, as is a toe falling off - methylphenidate induced Raynaud’s phenomenon. Sleep. 2022;45(SUPPL 1):A347. https://doi.org/10.1093/sleep/zsac079.796.

Article  Google Scholar 

Gimarc K, Junn C. Raynaud’s phenomenon with methylphenidate treatment in a patient with TBI. Journal of Head Trauma Rehabilitation. 2022;37(6):E588. https://doi.org/10.1097/HTR.0000000000000845.

Article  Google Scholar 

Gnanavel S. Lisdexamfetamine and secondary Raynaud's phenomenon. The Primary Care Companion for CNS Disorders. 2018;20(5). https://doi.org/10.4088/PCC.17l02240.

Gökçen C, Kutuk MO, Coşkun Ş. Dose-dependent Raynaud’s phenomenon developing from use of atomoxetine in a girl. J Child Adolesc Psychopharmacol. 2013;23(6):428–30. https://doi.org/10.1089/cap.2012.0131.

Article  PubMed  Google Scholar 

Gülcü Üstün NS, karayağmurlu A. Modified-release methylphenidate-induced Raynaud’s phenomenon in an adolescent with attention deficit hyperactivity disorder. Cukurova Med J. 2022;47(3):1381–3. https://doi.org/10.17826/cumj.1121992.

Article  Google Scholar 

Gülle ZN, Ali K, Murat C. Raynaud’s phenomenon related with atomoxetine treatment in a child with autism and attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2019;29(8):649–50.

Article  PubMed  Google Scholar 

Gupta M. Rare Side effects of stimulants: Raynaud's phenomenon. The Primary Care Companion for CNS Disorders. 2021;23(5). https://doi.org/10.4088/PCC.20l02857.

Iglesias OM. Secondary Raynaud’s phenomenon: case report. Reactions. 2015;1582:295–319.

Google Scholar 

Laboe C, Batchelder E, Vasireddy D. Persistent Raynaud’s phenomenon following methylphenidate hydrochloride use during the COVID-19 pandemic. Cureus. 2021;13(9): e17647. https://doi.org/10.7759/cureus.17647.

Article  PubMed  PubMed Central  Google Scholar 

Monteerarat Y, Pariwatcharakul P. Methylphenidate-induced Raynaud phenomenon developed after increasing methylphenidate in an adult with attention-deficit hyperactivity disorder. J Clin Psychopharmacol. 2019;39(2):178–9. https://doi.org/10.10